Wednesday, June 7, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

BARDA Issues 3 New Broad Agency Announcements for Biodefense

by Global Biodefense Staff
October 5, 2015

The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, has released three presolicitation Broad Agency Announcements (BAAs) in support of medical countermeasures development.

BARDA manages Project BioShield, which includes the procurement and advanced development of medical countermeasures for chemical, biological, radiological, and nuclear (CBRN) agents, as well as the advanced development and procurement of medical countermeasures for pandemic influenza and other emerging infectious diseases that fall outside the auspices of Project BioShield.

BARDA anticipates that advanced research and development contracts awarded under the following BAAs will advance the maturity and scientific understanding of candidate medical countermeasures, and result in a broader portfolio of products for potential consideration under future procurement activities.

BAA-16-100-SOL-00001 Advanced Research and Development of CBRN Medical Countermeasures

  • Vaccines
  • Antitoxins and Therapeutic Proteins
  • Antimicrobial Therapeutics
  • Radiological/Nuclear Threat Medical Countermeasures
  • Chemical Threat Medical Countermeasures
  • Clinical Diagnostics

BAA-16-100-SOL-00002 Advanced Development of Medical Countermeasures for Pandemic Influenza

  • Personal Protective Equipment (Mask and Respirators) for Influenza Infection for All- Hazards
  • Full-Featured Continuous Ventilators for Influenza and All-Hazards
  • Influenza Test Systems and Diagnostic Tools
  • Influenza Therapeutics
  • Influenza Vaccines

BAA-16-100-SOL-00003 Advanced Research and Development to Expedite the Identification, Development, and Manufacturing of Medical Countermeasures against Infectious Diseases

  • Platform Technologies to Expedite the Identification, Development, and Manufacturing of Medical Countermeasures against Infectious Diseases

BARDA will host a Multi-BAA Pre-Proposal Conference October 14-16, 2015 in Washington, D.C. to further discuss these funding opportunities. Advance registration is required.

Tags: AntimicrobialsAntitoxinsAntiviralsASPRBAABARDAHHSInfluenzaPOC DiagnosticsRuggedizedThermostability

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC